Elani Streja1, Hsin-Yi Wang1, Wei Ling Lau2, Miklos Z Molnar3, Csaba P Kovesdy4, Kamyar Kalantar-Zadeh5, Jongha Park6. 1. Harold Simmons Center for Kidney Disease Research & Epidemiology, University of California Irvine, School of Medicine, Orange, CA, USA. 2. Division of Nephrology and Hypertension, University of California Irvine, School of Medicine, Orange, CA, USA. 3. Harold Simmons Center for Kidney Disease Research & Epidemiology, University of California Irvine, School of Medicine, Orange, CA, USA; Division of Nephrology, University Health Network, University of Toronto, Toronto, ON, Canada. 4. Division of Nephrology, Memphis Veterans Affairs Medical Center, Memphis, TN, USA; University of Tennessee Health Science Center, Memphis, TN, USA. 5. Harold Simmons Center for Kidney Disease Research & Epidemiology, University of California Irvine, School of Medicine, Orange, CA, USA; Division of Nephrology and Hypertension, University of California Irvine, School of Medicine, Orange, CA, USA; Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, USA. Electronic address: kkz@uci.edu. 6. Harold Simmons Center for Kidney Disease Research & Epidemiology, University of California Irvine, School of Medicine, Orange, CA, USA; Division of Nephrology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea. Electronic address: jonghaparkmd@gmail.com.
Abstract
BACKGROUND: Mineral and bone disorder (MBD) is common and associated with mortality in patients with chronic kidney disease (CKD) Given that disarrays in serum phosphorus (P) and parathyroid hormone (PTH) levels and their changes over time are closely interrelated, modeling mortality-predictability of their combinations may help improve CKD patient management. METHODS: A historical cohort study was undertaken to evaluate the joint effect of serum P and PTH levels on mortality in 107,299 chronic hemodialysis (HD) patients. Changes in serum P and PTH levels over 6months, in particular discordant changes, were also modeled with mortality. RESULTS: HD patients were 64±15 (mean±SD)years old and included 45% women, 33% African-American, and 59% diabetic. Compared with serum P level ≥7.0mg/dL and PTH level ≥600pg/mL, adjusted hazard ratio (HR) tended to be lowest in patients with serum P level of 3.5-<5.5mg/dL combined with PTH level of 150-<300pg/mL (HR 0.64, 95% confidence interval 0.61-0.67). A change over time in serum P level towards the 3.5-<5.5mg/dL range from higher or lower ranges was associated with a decreased mortality, whereas only change in PTH level from <150pg/mL to 150-<300pg/mL range was associated with a lower risk of mortality. Upon discordant changes of PTH and P, i.e., decrease in one of the two measures while the other increased, no change in mortality risk was observed. CONCLUSION: In CKD-MBD management, patent survival is the greatest with controlling both serum P and PTH levels in balance. Tailoring an individualized treatment strategy in CKD-MBD may benefit patients. Further studies are needed.
BACKGROUND: Mineral and bone disorder (MBD) is common and associated with mortality in patients with chronic kidney disease (CKD) Given that disarrays in serum phosphorus (P) and parathyroid hormone (PTH) levels and their changes over time are closely interrelated, modeling mortality-predictability of their combinations may help improve CKDpatient management. METHODS: A historical cohort study was undertaken to evaluate the joint effect of serum P and PTH levels on mortality in 107,299 chronic hemodialysis (HD) patients. Changes in serum P and PTH levels over 6months, in particular discordant changes, were also modeled with mortality. RESULTS:HDpatients were 64±15 (mean±SD)years old and included 45% women, 33% African-American, and 59% diabetic. Compared with serum P level ≥7.0mg/dL and PTH level ≥600pg/mL, adjusted hazard ratio (HR) tended to be lowest in patients with serum P level of 3.5-<5.5mg/dL combined with PTH level of 150-<300pg/mL (HR 0.64, 95% confidence interval 0.61-0.67). A change over time in serum P level towards the 3.5-<5.5mg/dL range from higher or lower ranges was associated with a decreased mortality, whereas only change in PTH level from <150pg/mL to 150-<300pg/mL range was associated with a lower risk of mortality. Upon discordant changes of PTH and P, i.e., decrease in one of the two measures while the other increased, no change in mortality risk was observed. CONCLUSION: In CKD-MBD management, patent survival is the greatest with controlling both serum P and PTH levels in balance. Tailoring an individualized treatment strategy in CKD-MBD may benefit patients. Further studies are needed.
Authors: Tamara Isakova; Huiliang Xie; Wei Yang; Dawei Xie; Amanda Hyre Anderson; Julia Scialla; Patricia Wahl; Orlando M Gutiérrez; Susan Steigerwalt; Jiang He; Stanley Schwartz; Joan Lo; Akinlolu Ojo; James Sondheimer; Chi-yuan Hsu; James Lash; Mary Leonard; John W Kusek; Harold I Feldman; Myles Wolf Journal: JAMA Date: 2011-06-15 Impact factor: 56.272
Authors: Jessica Kendrick; Alfred K Cheung; James S Kaufman; Tom Greene; William L Roberts; Gerard Smits; Michel Chonchol Journal: J Am Soc Nephrol Date: 2011-09-07 Impact factor: 10.121
Authors: Francesca Tentori; Margaret J Blayney; Justin M Albert; Brenda W Gillespie; Peter G Kerr; Jürgen Bommer; Eric W Young; Tadao Akizawa; Takashi Akiba; Ronald L Pisoni; Bruce M Robinson; Friedrich K Port Journal: Am J Kidney Dis Date: 2008-06-02 Impact factor: 8.860
Authors: Ron Wald; Mark J Sarnak; Hocine Tighiouart; Alfred K Cheung; Andrew S Levey; Garabed Eknoyan; Dana C Miskulin Journal: Am J Kidney Dis Date: 2008-07-26 Impact factor: 8.860
Authors: Christian S Shinaberger; Sander Greenland; Joel D Kopple; David Van Wyck; Rajnish Mehrotra; Csaba P Kovesdy; Kamyar Kalantar-Zadeh Journal: Am J Clin Nutr Date: 2008-12 Impact factor: 7.045
Authors: Melissa Soohoo; Yoshitsugu Obi; Matthew B Rivara; Scott V Adams; Wei Ling Lau; Connie M Rhee; Csaba P Kovesdy; Kamyar Kalantar-Zadeh; Onyebuchi A Arah; Rajnish Mehrotra; Elani Streja Journal: Am J Nephrol Date: 2022-02-28 Impact factor: 4.605